CN101375944A - Pharmaceutical combination for preventing birth-defect and improving memory - Google Patents
Pharmaceutical combination for preventing birth-defect and improving memory Download PDFInfo
- Publication number
- CN101375944A CN101375944A CNA2008102238606A CN200810223860A CN101375944A CN 101375944 A CN101375944 A CN 101375944A CN A2008102238606 A CNA2008102238606 A CN A2008102238606A CN 200810223860 A CN200810223860 A CN 200810223860A CN 101375944 A CN101375944 A CN 101375944A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- zinc
- rhizoma atractylodis
- atractylodis macrocephalae
- chromium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000032170 Congenital Abnormalities Diseases 0.000 title claims abstract description 33
- 230000007698 birth defect Effects 0.000 title claims abstract description 32
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 81
- 239000011720 vitamin B Substances 0.000 claims abstract description 81
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 65
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 52
- 239000011651 chromium Substances 0.000 claims abstract description 39
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims abstract description 38
- 229910052804 chromium Inorganic materials 0.000 claims abstract description 38
- 239000011701 zinc Substances 0.000 claims abstract description 36
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 36
- 239000011669 selenium Substances 0.000 claims abstract description 34
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 33
- 239000010949 copper Substances 0.000 claims abstract description 29
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229910052802 copper Inorganic materials 0.000 claims abstract description 28
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims abstract description 27
- 229910052750 molybdenum Inorganic materials 0.000 claims abstract description 27
- 239000011733 molybdenum Substances 0.000 claims abstract description 27
- 239000011572 manganese Substances 0.000 claims abstract description 25
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims abstract description 24
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229910052748 manganese Inorganic materials 0.000 claims abstract description 24
- 229930003270 Vitamin B Natural products 0.000 claims description 80
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 52
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 44
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 41
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 26
- 229960000304 folic acid Drugs 0.000 claims description 26
- 235000019152 folic acid Nutrition 0.000 claims description 26
- 239000011724 folic acid Substances 0.000 claims description 26
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 22
- 229940055726 pantothenic acid Drugs 0.000 claims description 22
- 235000019161 pantothenic acid Nutrition 0.000 claims description 22
- 239000011713 pantothenic acid Substances 0.000 claims description 22
- 229960002685 biotin Drugs 0.000 claims description 20
- 235000020958 biotin Nutrition 0.000 claims description 20
- 239000011616 biotin Substances 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 8
- 239000011573 trace mineral Substances 0.000 abstract description 53
- 235000013619 trace mineral Nutrition 0.000 abstract description 53
- 239000003814 drug Substances 0.000 abstract description 23
- 229910052742 iron Inorganic materials 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 abstract description 7
- 206010010356 Congenital anomaly Diseases 0.000 abstract description 3
- 231100000957 no side effect Toxicity 0.000 abstract description 3
- 240000000249 Morus alba Species 0.000 abstract description 2
- 235000016709 nutrition Nutrition 0.000 abstract description 2
- 241000132012 Atractylodes Species 0.000 abstract 1
- 235000008708 Morus alba Nutrition 0.000 abstract 1
- 229930003316 Vitamin D Natural products 0.000 abstract 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 230000000474 nursing effect Effects 0.000 abstract 1
- 235000019166 vitamin D Nutrition 0.000 abstract 1
- 239000011710 vitamin D Substances 0.000 abstract 1
- 150000003710 vitamin D derivatives Chemical class 0.000 abstract 1
- 229940046001 vitamin b complex Drugs 0.000 abstract 1
- 229940046008 vitamin d Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 33
- 239000000203 mixture Substances 0.000 description 31
- 229940091258 selenium supplement Drugs 0.000 description 26
- 230000006870 function Effects 0.000 description 18
- 229940088594 vitamin Drugs 0.000 description 16
- 229930003231 vitamin Natural products 0.000 description 16
- 235000013343 vitamin Nutrition 0.000 description 16
- 239000011782 vitamin Substances 0.000 description 16
- 150000003722 vitamin derivatives Chemical class 0.000 description 15
- 239000002775 capsule Substances 0.000 description 13
- -1 physical factor Substances 0.000 description 13
- 230000002265 prevention Effects 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 230000036039 immunity Effects 0.000 description 12
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 11
- 239000000654 additive Substances 0.000 description 10
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 9
- 230000000996 additive effect Effects 0.000 description 9
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 9
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 9
- PMYDPQQPEAYXKD-UHFFFAOYSA-N 3-hydroxy-n-naphthalen-2-ylnaphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(NC(=O)C3=CC4=CC=CC=C4C=C3O)=CC=C21 PMYDPQQPEAYXKD-UHFFFAOYSA-N 0.000 description 8
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 229960002413 ferric citrate Drugs 0.000 description 8
- 230000004060 metabolic process Effects 0.000 description 8
- 235000018716 sodium selenate Nutrition 0.000 description 8
- 239000011655 sodium selenate Substances 0.000 description 8
- 229960001881 sodium selenate Drugs 0.000 description 8
- 235000000193 zinc lactate Nutrition 0.000 description 8
- 239000011576 zinc lactate Substances 0.000 description 8
- 229940050168 zinc lactate Drugs 0.000 description 8
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- 229910000323 aluminium silicate Inorganic materials 0.000 description 7
- 208000007502 anemia Diseases 0.000 description 7
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- 210000003754 fetus Anatomy 0.000 description 7
- 239000011777 magnesium Substances 0.000 description 7
- 229910052749 magnesium Inorganic materials 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 235000015393 sodium molybdate Nutrition 0.000 description 6
- 239000011684 sodium molybdate Substances 0.000 description 6
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000001093 anti-cancer Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- FWBOFUGDKHMVPI-UHFFFAOYSA-K dicopper;2-oxidopropane-1,2,3-tricarboxylate Chemical compound [Cu+2].[Cu+2].[O-]C(=O)CC([O-])(C([O-])=O)CC([O-])=O FWBOFUGDKHMVPI-UHFFFAOYSA-K 0.000 description 5
- 239000003925 fat Substances 0.000 description 5
- 229940089653 folic acid 0.3 mg Drugs 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000002607 hemopoietic effect Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000003064 anti-oxidating effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 239000007952 growth promoter Substances 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- 235000014872 manganese citrate Nutrition 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- OAVRWNUUOUXDFH-UHFFFAOYSA-H 2-hydroxypropane-1,2,3-tricarboxylate;manganese(2+) Chemical compound [Mn+2].[Mn+2].[Mn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O OAVRWNUUOUXDFH-UHFFFAOYSA-H 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 206010022971 Iron Deficiencies Diseases 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 206010048259 Zinc deficiency Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 239000011564 manganese citrate Substances 0.000 description 3
- 229940097206 manganese citrate Drugs 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 235000005152 nicotinamide Nutrition 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- 229960003966 nicotinamide Drugs 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010049865 Achromotrichia acquired Diseases 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 2
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010029400 Nicotinic acid deficiency Diseases 0.000 description 2
- 208000002141 Pellagra Diseases 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000170 anti-cariogenic effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 208000007287 cheilitis Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000000745 gonadal hormone Substances 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- 231100001022 leukopenia Toxicity 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 201000010193 neural tube defect Diseases 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 208000035581 susceptibility to neural tube defects Diseases 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- PNNHLULHRSZWPG-UHFFFAOYSA-J 1,5-dihydroxypentan-3-yl phosphate;2,3-dihydroxypropyl phosphate;manganese(2+) Chemical compound [Mn+2].[Mn+2].OCC(O)COP([O-])([O-])=O.OCCC(CCO)OP([O-])([O-])=O PNNHLULHRSZWPG-UHFFFAOYSA-J 0.000 description 1
- XMLHTAFIAXPIDG-UHFFFAOYSA-K 2-hydroxypropane-1,2,3-tricarboxylate;manganese(3+) Chemical class [Mn+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XMLHTAFIAXPIDG-UHFFFAOYSA-K 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010001557 Albinism Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000092665 Atractylodes macrocephala Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000003670 Carboxypeptidase B Human genes 0.000 description 1
- 108090000087 Carboxypeptidase B Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 229910021556 Chromium(III) chloride Inorganic materials 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 239000004277 Ferrous carbonate Substances 0.000 description 1
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
- DKKCQDROTDCQOR-UHFFFAOYSA-L Ferrous lactate Chemical compound [Fe+2].CC(O)C([O-])=O.CC(O)C([O-])=O DKKCQDROTDCQOR-UHFFFAOYSA-L 0.000 description 1
- 208000001362 Fetal Growth Retardation Diseases 0.000 description 1
- 206010070531 Foetal growth restriction Diseases 0.000 description 1
- 208000005232 Glossitis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- JJWSNOOGIUMOEE-UHFFFAOYSA-N Monomethylmercury Chemical compound [Hg]C JJWSNOOGIUMOEE-UHFFFAOYSA-N 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 206010036600 Premature labour Diseases 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 description 1
- RJFAYQIBOAGBLC-UHFFFAOYSA-N Selenomethionine Natural products C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- XSCQURIRMINZIY-UHFFFAOYSA-N [Se].COC(C1=CC=CC=C1)OC#N Chemical compound [Se].COC(C1=CC=CC=C1)OC#N XSCQURIRMINZIY-UHFFFAOYSA-N 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- FRHBOQMZUOWXQL-UHFFFAOYSA-L ammonium ferric citrate Chemical compound [NH4+].[Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FRHBOQMZUOWXQL-UHFFFAOYSA-L 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 201000003465 angular cheilitis Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002605 anti-dotal effect Effects 0.000 description 1
- 230000002790 anti-mutagenic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- 239000011805 ball Substances 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 244000144987 brood Species 0.000 description 1
- MDXRFOWKIZPNTA-UHFFFAOYSA-L butanedioate;iron(2+) Chemical compound [Fe+2].[O-]C(=O)CCC([O-])=O MDXRFOWKIZPNTA-UHFFFAOYSA-L 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 229960000359 chromic chloride Drugs 0.000 description 1
- 229940046374 chromium picolinate Drugs 0.000 description 1
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
- GJYSUGXFENSLOO-UHFFFAOYSA-N chromium;pyridine-2-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1 GJYSUGXFENSLOO-UHFFFAOYSA-N 0.000 description 1
- HPCCGRCEBFBZQP-UHFFFAOYSA-N chromium;pyridine-3-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CN=C1 HPCCGRCEBFBZQP-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 229940108925 copper gluconate Drugs 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- UBFWAFZODRGFIF-UHFFFAOYSA-N cyanic acid;selenium Chemical compound [Se].OC#N UBFWAFZODRGFIF-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000036654 deficiency anemia Diseases 0.000 description 1
- 239000013530 defoamer Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960004642 ferric ammonium citrate Drugs 0.000 description 1
- 235000019268 ferrous carbonate Nutrition 0.000 description 1
- RAQDACVRFCEPDA-UHFFFAOYSA-L ferrous carbonate Chemical compound [Fe+2].[O-]C([O-])=O RAQDACVRFCEPDA-UHFFFAOYSA-L 0.000 description 1
- 229960004652 ferrous carbonate Drugs 0.000 description 1
- 235000019850 ferrous citrate Nutrition 0.000 description 1
- 239000011640 ferrous citrate Substances 0.000 description 1
- 235000002332 ferrous fumarate Nutrition 0.000 description 1
- 239000011773 ferrous fumarate Substances 0.000 description 1
- 229960000225 ferrous fumarate Drugs 0.000 description 1
- 235000013924 ferrous gluconate Nutrition 0.000 description 1
- 239000004222 ferrous gluconate Substances 0.000 description 1
- 229960001645 ferrous gluconate Drugs 0.000 description 1
- 235000013925 ferrous lactate Nutrition 0.000 description 1
- 239000004225 ferrous lactate Substances 0.000 description 1
- 229940037907 ferrous lactate Drugs 0.000 description 1
- 229960001604 ferrous succinate Drugs 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 208000030941 fetal growth restriction Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229940063755 folic acid 0.1 mg Drugs 0.000 description 1
- 229940083563 folic acid 1 mg Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- BTIJJDXEELBZFS-UHFFFAOYSA-K hemin Chemical compound [Cl-].[Fe+3].[N-]1C(C=C2C(=C(C)C(C=C3C(=C(C)C(=C4)[N-]3)C=C)=N2)C=C)=C(C)C(CCC(O)=O)=C1C=C1C(CCC(O)=O)=C(C)C4=N1 BTIJJDXEELBZFS-UHFFFAOYSA-K 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 235000000011 iron ammonium citrate Nutrition 0.000 description 1
- 239000004313 iron ammonium citrate Substances 0.000 description 1
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000015 iron(II) carbonate Inorganic materials 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 231100000863 loss of memory Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- 235000014012 manganese gluconate Nutrition 0.000 description 1
- 239000011683 manganese gluconate Substances 0.000 description 1
- 229940072543 manganese gluconate Drugs 0.000 description 1
- 235000018348 manganese glycerophosphate Nutrition 0.000 description 1
- 239000011584 manganese glycerophosphate Substances 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- OXHQNTSSPHKCPB-IYEMJOQQSA-L manganese(2+);(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Mn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OXHQNTSSPHKCPB-IYEMJOQQSA-L 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 231100001016 megaloblastic anemia Toxicity 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 208000026440 premature labor Diseases 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- 229960002718 selenomethionine Drugs 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 231100000462 teratogen Toxicity 0.000 description 1
- 239000003439 teratogenic agent Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 229960000314 zinc acetate Drugs 0.000 description 1
- 235000013904 zinc acetate Nutrition 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
- 229940043825 zinc carbonate Drugs 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 229960001939 zinc chloride Drugs 0.000 description 1
- 235000006076 zinc citrate Nutrition 0.000 description 1
- 239000011746 zinc citrate Substances 0.000 description 1
- 229940068475 zinc citrate Drugs 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 229940110280 zinc methionine Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- CNMFGFBWPBBGKX-SCGRZTRASA-L zinc;(2s)-2-amino-4-methylsulfanylbutanoate Chemical compound [Zn+2].CSCC[C@H](N)C([O-])=O.CSCC[C@H](N)C([O-])=O CNMFGFBWPBBGKX-SCGRZTRASA-L 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A medicament combination used for preventing birth defects and improving memory comprises Atractylodes rhizome, mulberry, vitamin B complex, vitamin D, as well as trace elements o zinc, selenium, iron, chromium, copper, molybdenum, and manganese. The medicament combination is mainly suitable for pregestational women, pregnant women and nursing mothers, and is very effective in preventing the birth defects and improving the memory. Meanwhile, the medication combination has healthcare and nutritional efficacies, and causes no side effect even after long-term administration.
Description
Technical field: the present invention relates to the Medicines and Health Product technical field; Pharmaceutical composition in particular for prevention birth defect and improvement memory.
Background technology: birth defect is meant that fetus is in parent and in the organ formative process of birth back, by embryo due to the various factors effect and paedomorphosis disorder, comprise that morphosis is unusual, 4 types of physiological metabolism obstacle, congenital mental retardation and intrauterine growth retardations etc.; Various countries' birth defect incidence rate is up to about 5% of the birth sum, and is great to the population quality influence, causes white elephant for family, society, become the common great public health problem of paying close attention in the present whole world.
The pathogenic factors of birth defect is very complicated, and inherited genetic factors is arranged, and environmental factors also has other multiple uncertain factor.Environmental factors comprises biological factor, physical factor, chemical factor; The embryo is subjected to the injury of environment harmful factor and other multiple uncertain factor, the birth defect sickness rate is increased, and eliminate these harmful factors, and the birth defect sickness rate is lowered.
Pharmaceutical composition of the present invention is a policy of following prenatal and postnatal care, by eliminating the birth defect factor that causes to the embryo, the generation of prevention birth defect reaches the purpose that lowers the birth defect sickness rate, simultaneously user there is the memory impairments of improvement, favourable mothers and sons two generations's health; Said composition comprises the Rhizoma Atractylodis Macrocephalae and Fructus Mori, compound vitamin B and trace element zinc, selenium, ferrum, chromium, copper, molybdenum, manganese.
The Rhizoma Atractylodis Macrocephalae is a kind of QI invigorating class natural Chinese medicine, and invigorating the spleen and benefiting QI is arranged, the dampness diuretic, the hidroschesis consolidating superficial resistance and in antiabortive effect; Ancient Chinese medicine is classified the Rhizoma Atractylodis Macrocephalae as on Chinese medicine product, antiabortive monarch drug, the panacea of fetus nourishing; The modern clinical cirrhotic ascites that are used for more, diarrhoea, Mo Niai syndrome, edema spontaneous perspiration, frequent fetal movement etc.; Modern pharmacological research confirms: 1, Rhizoma Atractylodis Macrocephalae Wheat Protein, can alleviate lipid peroxidation, reduce the content of peroxide, avoid the destruction of harmful substance pair cell 26S Proteasome Structure and Function, and SOD activity improving trend arranged, enhancing body is to the ability of free radical scavenging, thus the damage of minimizing radical pair body; 2, the Rhizoma Atractylodis Macrocephalae has delaying senility function, Rhizoma Atractylodis Macrocephalae decoct can improve the erythrocytic superoxide dismutase of aged mouse (SOD) activity, suppresses the brain activity of monoamine oxidase simultaneously, can also suppress erythrocytic autoxidation haemolysis, directly remove free radical, show anti-aging effects; 3, the Rhizoma Atractylodis Macrocephalae has the enhance immunity effect, and oral lymhocyte transformation rate and the serum IgG content of making of Rhizoma Atractylodis Macrocephalae decoct significantly rises, and shows that the Rhizoma Atractylodis Macrocephalae has immunostimulation, and can strengthen the vigor of macrophage, strengthens the phagocytic function of reticuloendothelial system; 4, anticancer tumor effect, Rhizoma Atractylodis Macrocephalae volatile oil has inhibitory action to murine sarcoma S180, and external have direct killing action to the ehrlich ascites tumor cell, and external the Eca109 esophageal cancer cell is presented inhibition, can make cell detachment, karyopycnosis, chromatin concentrates, and cell does not divide or seldom division; 5, the Rhizoma Atractylodis Macrocephalae also has the blood lipid-reducing blood sugar-decreasing effect, antibacterial action, and blood coagulation resisting function promotes the brood weight increase, physical potentiation raises to can be made leukocyte count by the leukopenia that causes after chemotherapy or the radiotherapy tumor; Traditional Chinese medical science custom in prescription the compatibility Rhizoma Atractylodis Macrocephalae with the absorption, particularly compatibility gold that promote the medicine active ingredient, stone class medicine to promote the absorption and the utilization of mineral; The Rhizoma Atractylodis Macrocephalae is the article that can be used for health food.
Fructus Mori be a kind of be food also be the nourishing YIN class natural Chinese medicine of medicine, nourishing YIN and supplementing blood is arranged, the intestine moistening of promoting the production of body fluid, the effect of the liver and the kidney tonifying; Clinical be used to calm the nerves nourish heart slow down aging; The treatment early whitening of beard and hair, body fluid deficiency is quenched one's thirst, diseases such as blood deficiency and constipation; Modern pharmacological research confirms that Fructus Mori has: 1, raise immunity; 2, hemopoietic; 3, anti-oxidation function; 4, antimutagenesis; 5, delaying senility function; 6, rising peripheral leukocytes effect etc.
Vitamin B group participates in body internal protein, fat and sugar metabolism, makes the excitement of brain cell and inhibition be in poised state, and it comprises vitamin B
1, vitamin B
2, nicotiamide, pantothenic acid, biotin, vitamin B
6, vitamin B
12, folic acid etc., collaborative in vivo performance physiological action.Vitamin B
1Have the effect of keeping the nervous system normal function, phenomenon such as it is incomplete to occur carbohydrate metabolism during shortage, and heat energy is under-supply, thus cause hypomnesis, influence the normal function of brain, if vitamin B
1Abundance can effectively form the energy of brain cell activity necessity, but improving memory, concentration power and learning capacity, vitamin B in addition
1Suppress cholinesterase in addition, improve the function of cholinergic nerve; Vitamin B
2Having another name called riboflavin, is the ingredient of many important coenzyme in the body, and it participates in intravital substance metabolism, promotes fetus and baby's growth promoter to play an important role vitamin B to the activity that earns a bare living
2Be to keep skin and the requisite vitamin of eye health, anemia of pregnant woman's vitamin B
2Lack or can not cause or inspire pregnant early pregnancy completely and vomit, second trimester angular cheilitis, glossitis, cheilitis and premature infant's incidence rate increase; Nicotiamide claims niacin amide or vitamin PP again, and its physiological function is to participate in the body intracellular metabolic, keeps normal neurological function, and pellagra can take place during shortage in synthesizing of assurance gonadal hormone etc., mainly shows as dermatitis, diarrhoea, dull-witted three big symptoms; Pantothenic acid extensively exists in each organism, participates in metabolic activity widely, and known have 70 plurality of enzymes all to need pantothenic acid to participate in all kinds of biochemical reaction of catalysis body, otherwise just can Metabolic disorder; Biotin also is a kind of vitamin B group, coordinates to participate in the metabolism of human body matter and energy with other vitamin B group, and it is synthetic with nucleic acid, and the compositive relation of gonadal hormone is close, and it also has control poliosis, bareheaded effect; Vitamin B
6Most important to the maincenter neurodevelopment, if shortage can make the nervus centralis hypoevolutism, intelligence descends, and it has the assistance vitamin B
1Effect, be the vitamin that can improve concentration power and stimulate desire learn; Vitamin B
12Participate in nucleic acid in vivo, choline, amino acid whose synthetic and fat and sugared metabolism, to hemopoietic function of bone marrow, the gastrointestinal epithelial cells function, liver function and nervous system myelin functional integrity have certain effect, it is the necessary vitamin of intelligence of bringing into normal play, not only cause dysnoesia if lack, also nutritional anemia can occur, influence is to blood supply in the brain; Folic acid participates in the synthetic of aminoacid and nucleic acid, and and vitamin B
12The common generation that promotes cell is with ripe, and normal cell can not carry out mitosis during shortage, the neurological symptom can occur, as: the loss of memory, depression and dementia etc.; Human body can be at vitamin B in addition
12Under the effect of folic acid as cofactors, by serine of taking in and the synthetic choline of methionine, choline is the key component of acetylcholine, and acetylcholine is an important neurotransmitter in the human body; Folic acid, vitamin B are arranged again
6And vitamin B
12Can work in coordination with and remove the intravital homotype cysteine of people, the homotype cysteine is a kind of neurotoxin, can cause the self murder of brain; There are some researches show that homocysteine is a kind of potential teratogen of independently growing, and is related closely with congenital heart disease and neural tube defects; Homocysteine also can cause miscarriage, premature labor in addition, clinical disastrous effect such as preeclampsia.
Trace element zinc is merged in the biomacromolecule ligand---in protein, nucleic acid, the film (being mainly memebrane protein), generate stable metallic biomacromolecule complex---metalloprotein, metalloproteinase nucleic acid complex etc., at present, known these materials participate in the synthetic and degradation process of carbohydrate, lipid, protein and nucleic acid, and the existence of zinc enzyme is all arranged in six big fermentoids; Zinc also is the essential element of enhance immunity vigor; Zinc can promote that proinsulin is converted into insulin by activating protaminase, and zinc deficiency makes insulin be obstructed in the activity of peripheral tissues, and it is unusual to cause glucose tolerance curve; Anemia of pregnant woman's zinc deficiency can influence the growth promoter of fetus to some extent, so that causes all deformities of fetus; Zinc deficiency can cause brain development bad, incomplete development of mind.
Trace element-selenium has obvious reduction serum total cholesterol, triglyceride and lipid peroxide, improves high density lipoprotein, the metabolic effect of superabundant fats in the acceleration bodies; Selenium also has the strong anti-oxidation function, and the protection embryo is not subjected to the injury of superoxides, prevention of cardiac; Anticancer by enhance immunity recognition system removing cancerous cell; Remove and the drainage heavy metal ion, hydrargyrum, methyl mercury, cadmium, lead etc. are had Detoxication, and heavy metal pollution is mainly to cause the birth defect factor; Scarce selenium can make the human insulin secretion reduce, impaired glucose tolerance, and oxidation resistance descends and quickens human senility and intelligence decline.
The major physiological function of trace elements iron is as hemoglobin, Myoglobin, and the ingredient of cytochrome etc. participates in transporting and the Tissue respiration process of the interior oxygen of body; In the conveying of oxygen and electronics, play central role; Contain ferrum in the catalatic structure, and hydrogen peroxide relies on catalatic degraded, hydrogen peroxide is a free radical the most dangerous in the human body; Iron deficiency is common in infant, anemia of pregnant woman and wet nurse, causes iron deficiency anemia, and its cardinal symptom is to have a delicate constitution, and memory weakens, and ability to work descends, and iron deficiency also can exert an influence to other system of human body; As the nervous system iron deficiency, can affect the nerves conduction and make the child occur that intelligence reduces and behavior disorder.
Chromium is a kind of essential trace element, has only trivalent chromium can be used for the supplement of chromium, and it can strengthen and promote the physiological action of insulin, and it can harden by prevention of arterial, and raise immunity promotes growth promoter; Scarce chromium can cause growth promoter to be stagnated, and quickens old and feeble.
Copper in human body mainly the form with the copper-containing metal enzyme play a role, participate in utilization, hemopoietic, phospholipid synthetic of ferrum, a series of metabolic processes such as collagenic connective tissue formation; The shortage of copper can cause collagen cross-linking obstacle in the connective tissue, heart disease and anemia, leukopenia, and arterial wall elasticity weakens, albinism etc.
Molybdenum is one of micro elements needed by human, it is the formation element of plurality of enzymes, participate in the utilization of ferrum, promote erythrocytic growth and maturation, can prevent anemia, and can help the metabolism of carbohydrate and fat, it participates in removing the murder by poisoning of poisonous aldehydes in the human body, eliminate human free radical, have anticancer, defying age, enhancing immunity and anticariogenic function; Scarce molybdenum can bring out cardiovascular disease, cancer and dental caries.
Manganese participates in the formation of some enzymes in human body, it is the metabolism of involved in sugar and lipid not only, and all works in protein, DNA and RVA are synthetic.
Application contains the Rhizoma Atractylodis Macrocephalae, Fructus Mori, vitamin B
1, vitamin B
2, vitamin B
6, nicotiamide, pantothenic acid, biotin, vitamin B
12, folic acid and trace element zinc, selenium, ferrum, chromium, copper, molybdenum, manganese has been known as the compositions of active component, but with the Rhizoma Atractylodis Macrocephalae and Fructus Mori, vitamin B
1, vitamin B
2, nicotiamide, pantothenic acid, biotin, vitamin B
6, vitamin B
12, folic acid and trace element zinc, selenium, ferrum, chromium, copper, molybdenum, the manganese compatibility pharmaceutical composition that is used for prenatal and postnatal care prevention birth defect and improves memory report as yet.
Current medicine that is used to improve memory or health food kind have multiple, but aim at pregnant before the medicine or the health food that are used to improve memory of women, anemia of pregnant woman, wet nurse's development do not see as yet; Do not see the medicine label that is used to prevent birth defect as yet, rarely seen report that folic acid prevention neural tube defects is arranged; But its target spot is few, and the link shortcoming needs perfect; And will prevent the effect of birth defect and improvement memory and be used for same medicine person not see as yet.
Summary of the invention: in order to overcome existing prevention birth defect and/or to improve the shortcoming and defect of remembering medicine, the purpose of this invention is to provide a kind of compositions, said composition promotes the absorption and the utilization of vitamin, mineral by the Rhizoma Atractylodis Macrocephalae, and with the collaborative vitamin B that increases of Fructus Mori
1, vitamin B
2, vitamin B
6, nicotiamide, pantothenic acid, biotin, vitamin B
12, folic acid and trace element zinc, selenium, ferrum, chromium, copper, molybdenum, manganese improves the effect of memory and prevention birth defect, simultaneously by trace element zinc, selenium, ferrum, chromium, copper, molybdenum, manganese and vitamin B
1, vitamin B
2, nicotiamide, pantothenic acid, biotin, vitamin B
6, vitamin B
12, folic acid, replenish and strengthen the antiabortive and Rhizoma Atractylodis Macrocephalae of Rhizoma Atractylodis Macrocephalae fetus nourishing and Fructus Mori antioxidation, defying age, enhance immunity, promotion hemopoietic, antimutagenic effect, even chronic administration is also without any side effect; Because the result of broad research, the inventor have found the Rhizoma Atractylodis Macrocephalae and Fructus Mori, vitamin B
1, vitamin B
2, nicotiamide, pantothenic acid, biotin, vitamin B
6, vitamin B
12, folic acid and trace element zinc, selenium, ferrum, chromium, copper, molybdenum, manganese novel combination, this novel combination is for the prevention birth defect and improve memory synergy is arranged; And singly use the Rhizoma Atractylodis Macrocephalae and Fructus Mori, compound vitamin B and trace element zinc, selenium, ferrum, chromium, copper, molybdenum, manganese, its effect is all not as good as this compositions; And the effective ingredient of each component has the addition complementary action to the health care tonification of human body, as the Rhizoma Atractylodis Macrocephalae of the used dosage of this compositions have that fetus nourishing is antiabortive, the effect of defying age, enhance immunity, physical strength reinforcing; Fructus Mori has nourishing YIN and supplementing blood, the effect of the intestine moistening of promoting the production of body fluid, the liver and the kidney tonifying; Trace element zinc is the necessary material of zinc enzyme in the interior six big fermentoids of human body, also is the essential element of enhance immunity vigor; But the metabolism of superabundant fats has the strong anti-oxidation function, prevention of cardiac function, anti-cancer function etc. in the trace element-selenium acceleration bodies; Trace elements iron participates in transporting and the Tissue respiration process of the interior oxygen of body, is the only element that prevents iron deficiency anemia; Trace element chromium has prevention of arterial sclerosis, enhance immunity, antidotal function; Trace copper participates in utilization, hemopoietic, phospholipid synthetic of ferrum; Trace element molybdenum has anticancer, defying age, enhance immunity and anticariogenic function; Trace element manganese participates in the synthetic of protein, DNA and RNA; Vitamin B
1Can prevent and treat vitamin B1 deficiency, keep the normal activity of nerve, digestion, muscle, blood circulation; Vitamin B
2Be to keep skin and the requisite vitamin of eye health; Pellagra can take place in nicotinamide deficiency; The pantothenic acid shortage can cause Metabolic disorder; Biotin can be prevented and treated poliosis, alopecia; Vitamin B
6Can eliminate intraepithelial neoplasia cells, raise immunity, the protection blood vessel; Vitamin B
12Be used for various megaloblastic anemias and neural disease; Folic acid is protected heart and antitumaous effect in addition; There is not incompatibility in this compositions, have no side effect, and cost is low, thereby constitutes the present invention.
The invention provides the pharmaceutical composition that is used to prevent birth defect and improves memory, it comprises as the Rhizoma Atractylodis Macrocephalae of active component and Fructus Mori, vitamin B
1, vitamin B
2, nicotiamide, pantothenic acid, biotin, vitamin B
6, vitamin B
12, folic acid and trace element zinc, selenium, ferrum, chromium, copper, molybdenum, manganese.
The Rhizoma Atractylodis Macrocephalae is a Compositae herbaceos perennial Rhizoma Atractylodis Macrocephalae Atractylodes macrocephala koidz. rhizome, main product in Zhejiang, ground such as Hubei, Hunan, gather winter, dry or dry, give birth to or parching with earth, parched with bran use; The used Rhizoma Atractylodis Macrocephalae of the present invention can be with its extract as raw material.
Fructus Mori is the fruit ear of Moraceae deciduous tree plant Mulberry Morus alba L., and all produce in national most of area, ground such as main product Sichuan, Jiangsu, Zhejiang, Shandong, peace are little, Liaoning, Henan and Shanxi, and the used Fructus Mori of the present invention can be with its extract as raw material.
Be used for vitamin B of the present invention
1(VitaminB
1), vitamin B
2(VitaminB
2), nicotiamide (Nicotinamide), pantothenic acid (Pantothenic Acid), biotin (Vitamin H), vitamin B
6(VitaminB
6), vitamin B
12(VitaminB
12), folic acid (Folic Acid), vitamin C (VitaminC), all are water soluble vitamins, do not accumulate in vivo; Zinc (Zn), selenium (Se), ferrum (Fe), chromium (Cr), copper (Cu), molybdenum (Mo) are micro elements needed by human, and manganese (Mn) is human body possibility essential trace element; Trace element zinc among the present invention can be selected zinc citrate for use, zinc acetate, zinc carbonate, zinc oxide, zinc chloride, zinc lactate, zinc sulfate, zinc gluconate, single zinc methionine etc., trace element-selenium can be selected Selenomethionine for use, methoxybenzyl cyanic acid selenium, the two cyanic acid selenium of phenylene, sodium selenite, selenocarrageenan, selenocysteine, the selenizing methionine, sodium selenate etc., trace elements iron can be selected Ferrous gluconate for use, ferrous lactate, ferric ammonium citrate, iron chloride, ferric citrate, ferrous carbonate, ferrous citrate, ferrous fumarate, heme iron, ferric phrophosphate, protohemin, ferrous succinate, ferrous sulfate etc., trace element chromium can be selected chromium trichloride for use, nicotinic acid chromium, chromium picolinate, chromium yeast etc., trace copper can be selected curpic carbonate for use, copper citrate, copper gluconate, copper sulfate etc., trace element molybdenum can be selected ammonium molybdate for use, sodium molybdate etc., trace element manganese can be selected manganese sulfate for use, manganese chloride, manganese gluconate, manganese glycerophosphate, manganese citrates etc. all have professional production factory and supplier.
Compositions of the present invention mainly is applicable to women in pregnant early stage, anemia of pregnant woman and wet nurse; Be subjected to the influence of factors such as geology, food chain, dietetic life custom and Time of Administration length, the effective dose that the crowd that benefits from benefits from this compositions each component has certain difference; By the present invention, the effective dose of Rhizoma Atractylodis Macrocephalae extract is counted 300-15000mg/ days with whole crude drug, and the effective dose of Fructus Mori extract is counted 300-10000mg/ days with whole crude drug, vitamin B
1Effective dose be 0.5-20mg/ days, vitamin B
2Effective dose be 0.5-20mg/ days, the effective dose of nicotiamide is 5-50mg/ days, the effective dose of pantothenic acid is 2-20mg/ days, the effective dose of biotin is 0.01-0.1mg/ days, vitamin B
6Effective dose be 0.5-10mg/ days, vitamin B
12Effective dose be 0.001-0.025mg/ days, the effective dose of folic acid is 0.1-1mg/ days, the effective dose of trace element zinc is counted 5-20mg/ days with element zinc, and selenic effective dose is counted 0.015-0.1mg/ days with elemental selenium, and the effective dose of ferrum is counted 5-20mg/ days with elemental iron.The effective dose of chromium is counted 0.015-0.15mg/ days with elemental chromium, and the effective dose of copper is counted 0.5-1.5mg/ days with elemental copper, and molybdenic effective dose is counted 0.02-0.06mg/ days with molybdenum, and the effective dose of manganese is counted 1-3mg/ days with element manganese.
Compositions of the present invention can or directly be taken by following pharmaceutical dosage forms dispenser, for example, oral formulations is (as granule, powder, capsule, ball, sheet, dry syrup, liquid formulation), or food such as food (as cookies), mix and prepare with other known additives, this class additive is for example: carrier, disintegrating agent, slow releasing agent, excipient, filler, covering, binding agent, lubricant, antioxidant, apply agent, coloring agent, correctives, sweeting agent, sucrose succedaneum, nutrition enhancer, flavouring agent, surfactant, plasticizer, the PH regulator, freshener, suspending agent, defoamer, antiseptic, thickening agent, solubilisation aids etc. are prepared or they are added food as functional component or additive by usual way.
By the present invention, the Rhizoma Atractylodis Macrocephalae, Fructus Mori, vitamin B
1, vitamin B
2, nicotiamide, pantothenic acid, biotin, vitamin B
6, vitamin B
12, folic acid and trace element zinc, selenium, ferrum, chromium, copper, molybdenum, manganese each component can distinguish preparation, the preparation of each component can be mixed the back when using and use or do not mix simultaneously and use.
Advantage of the present invention is that this compositions is eliminated the multiple factor that causes birth defect and cause hypomnesis from too many levels, multisystem, many target spots, the effect of collaborative performance effect is arranged between the each component, prevention birth defect and improvement memory there is significant effect, sufficient raw, cost is low, and each component has no side effect in the compositions, no incompatibility, except that prevention birth defect and improvement memory, human body still there is the health care benefiting action.
Subordinate list 1 is this compositions and the Rhizoma Atractylodis Macrocephalae and Fructus Mori component and the young rat/mouse labyrinth test effect comparison of vitamin added elements component.
Subordinate list 2 is this compositions and the Rhizoma Atractylodis Macrocephalae and Fructus Mori component and the comparison of vitamin added elements component Aged Mice maze test effect.
Relatively tabulate below with reference to embodiment and test implementation example effect and to be described in detail the present invention.
Embodiment 1:
Rhizoma Atractylodis Macrocephalae 2000mg,
Fructus Mori 500mg,
Folic acid 0.3mg,
Vitamin B
62mg,
Vitamin B
120.003mg,
Vitamin B
13mg,
Vitamin B
23mg,
Nicotiamide 10mg,
Zinc lactate (in trace element zinc) 10mg,
Sodium selenate (in trace element-selenium) 0.02mg,
Ferric citrate (in trace elements iron) 10mg.
Said components is further mixed equably with the additive of appropriate amount such as aluminosilicate magnesium, poly-solvate 60 and propylene glycol, the gained mixture is inserted capsule equably and 9 capsules, every day 3 times, each 3 capsules.
Embodiment 2:
Rhizoma Atractylodis Macrocephalae 2000mg,
Fructus Mori 500mg,
Folic acid 0.3mg,
Vitamin B
62mg,
Vitamin B
120.003mg,
Vitamin B
13mg,
Vitamin B
23mg,
Nicotiamide 10mg,
Zinc lactate (in trace element zinc) 8mg,
Sodium selenate (in trace element-selenium) 0.02mg,
Ferric citrate (in trace elements iron) 10mg,
Chromium yeast (in trace element chromium) 0.02mg,
Said components is further mixed equably with the additive of appropriate amount such as aluminosilicate magnesium, poly-solvate 60 and propylene glycol, the gained mixture is inserted capsule equably and 9 capsules, every day 3 times, each 3 capsules.
Embodiment 3:
Rhizoma Atractylodis Macrocephalae 2000mg,
Fructus Mori 500mg,
Folic acid 0.3mg,
Vitamin B
62mg,
Vitamin B
120.003mg,
Vitamin B
13mg,
Vitamin B
23mg,
Nicotiamide 10mg,
Zinc lactate (in trace element zinc) 8mg,
Sodium selenate (in trace element-selenium) 0.02mg,
Ferric citrate (in trace elements iron) 10mg,
Chromium yeast (in trace element chromium) 0.02mg,
Sodium molybdate (in trace element molybdenum) 0.03mg.
Said components is further mixed equably with the additive of appropriate amount such as aluminosilicate magnesium, poly-solvate 60 and propylene glycol, the gained mixture is inserted capsule equably and 9 capsules, every day 3 times, each 3 capsules.
Embodiment 4:
Rhizoma Atractylodis Macrocephalae 2000mg,
Fructus Mori 500mg,
Folic acid 0.3mg,
Vitamin B
62mg,
Vitamin B
120.003mg,
Vitamin B
13mg,
Vitamin B
23mg,
Nicotiamide 10mg,
Zinc lactate (in trace element zinc) 10mg,
Sodium selenate (in trace element-selenium) 0.02mg,
Ferric citrate (in trace elements iron) 10mg,
Chromium yeast (in trace element chromium) 0.02mg,
Copper citrate (in trace copper) 0.8mg,
Sodium molybdate (in trace element molybdenum) 0.03mg.
Said components is further mixed equably with the additive of appropriate amount such as aluminosilicate magnesium, poly-solvate 60 and propylene glycol, the gained mixture is inserted capsule equably and 9 capsules, every day 3 times, each 3 capsules.
Embodiment 5:
Rhizoma Atractylodis Macrocephalae 2000mg,
Fructus Mori 500mg,
Folic acid 0.3mg,
Vitamin B
62mg,
Vitamin B
120.003mg,
Vitamin B
13mg,
Vitamin B
23mg,
Nicotiamide 10mg,
Zinc lactate (in trace element zinc) 10mg,
Sodium selenate (in trace element-selenium) 0.02mg,
Ferric citrate (in trace elements iron) 10mg,
Chromium yeast (in trace element chromium) 0.02mg,
Copper citrate (in trace copper) 0.8mg,
Sodium molybdate (in trace element molybdenum) 0.03mg,
Manganese citrate (in trace element manganese) 1mg.
Above-mentioned component is further mixed equably with additive such as mannitol, hydroxypropyl cellulose, aluminosilicate magnesium and the flavoring agent of appropriate amount, again the gained mixture is made 3 bag shot-like particles; Obey every day 3 times, obey a bag at every turn.
Embodiment 6:
Rhizoma Atractylodis Macrocephalae 300mg,
Fructus Mori 300mg,
Folic acid 0.1mg,
Vitamin B
60.5mg,
Vitamin B
120.001mg,
Vitamin B
10.5mg,
Vitamin B
20.5mg,
Nicotiamide 5mg,
Pantothenic acid 2mg,
Biotin 0.01mg,
Zinc lactate (in trace element zinc) 5mg,
Sodium selenate (in trace element-selenium) 0.015mg,
Ferric citrate (in trace elements iron) 5mg,
Chromium yeast (in trace element chromium) 0.015mg,
Copper citrate (in trace copper) 0.5mg,
Sodium molybdate (in trace element molybdenum) 0.02mg,
Manganese citrate (in trace element manganese) 1mg.
Above-mentioned component is further mixed equably with additive such as mannitol, hydroxypropyl cellulose, aluminosilicate magnesium and the flavoring agent of appropriate amount, again the gained mixture is made 3 bag shot-like particles; Obey every day 3 times, obey a bag at every turn.
Embodiment 7:
Rhizoma Atractylodis Macrocephalae 15000mg,
Fructus Mori 10000mg,
Folic acid 1mg,
Vitamin B
610mg,
Vitamin B
120.025mg,
Vitamin B
120mg,
Vitamin B
220mg,
Nicotiamide 50mg,
Pantothenic acid 20mg,
Biotin 0.1mg,
Zinc lactate (in trace element zinc) 20mg,
Sodium selenate (in trace element-selenium) 0.1mg,
Ferric citrate (in trace elements iron) 20mg,
Chromium yeast (in trace element chromium) 0.15mg,
Copper citrate (in trace copper) 1.5mg,
Sodium molybdate (in trace element molybdenum) 0.06mg,
Manganese citrate (in trace element manganese) 3mg.
Above-mentioned component is further mixed equably with additive such as mannitol, hydroxypropyl cellulose, aluminosilicate magnesium and the flavoring agent of appropriate amount, again the gained mixture is made 3 bag shot-like particles; Obey every day 3 times, obey a bag at every turn, serve on 10, withdrew 3, obeyed again 10.
Confirm that through animal experiment this compositions belongs to nontoxic level; The crowd takes and does not also see toxicity.
Subordinate list 1: be this compositions and the Rhizoma Atractylodis Macrocephalae and Fructus Mori component and the young rat/mouse labyrinth test effect comparison of vitamin added elements component:
Group | Medicine | Consumption | Sample number | The mistake percentage rate |
The A group | Matched group | 0 | 12 | 21.6% |
The B group | The Rhizoma Atractylodis Macrocephalae and Fructus Mori group | Rhizoma Atractylodis Macrocephalae 100mg+ Fructus Mori 50mg/ days | 12 | 18.6% |
The C group | Vitamin+element set | Zinc 0.1mg+ ferrum 0.1mg+ selenium 0.001mg+ VB 10.1mg+VB 20.1mg+ nicotiamide 0.2mg+VB 60.08mg+VB 120.0001mg+ folic acid 0.008mg/ days | 12 | 15.8% |
The D group | The Rhizoma Atractylodis Macrocephalae and Fructus Mori+vitamin+element set | Rhizoma Atractylodis Macrocephalae 100mg+ Fructus Mori 50mg+ zinc 0.1mg+ ferrum 0.1mg+ selenium 0.001mg+VB 10.1mg+ VB 20.1mg+ nicotiamide 0.2mg+VB 60.08mg +VB 120.0001mg+ folic acid 0.008mg/ days | 12 | 14.9% |
Subordinate list 2: be this compositions and the Rhizoma Atractylodis Macrocephalae and Fructus Mori component and the comparison of vitamin added elements component Aged Mice maze test effect:
Group | Medicine | Consumption | Sample number | The mistake percentage rate |
The A group | Matched group | 0 | 12 | 53.3% |
The B group | The Rhizoma Atractylodis Macrocephalae and Fructus Mori group | Rhizoma Atractylodis Macrocephalae 100mg+ Fructus Mori 50mg/ days | 12 | 34.4% |
The C group | Vitamin+element set | Zinc 0.1mg+ ferrum 0.1mg+ selenium 0.001mg+ VB 10.1mg+VB 20.1mg+ nicotiamide 0.2mg+VB 60.08mg +VB 120.0001mg+ folic acid 0.008mg/ days | 12 | 31.4% |
The D group | The Rhizoma Atractylodis Macrocephalae and Fructus Mori+vitamin+element set | Rhizoma Atractylodis Macrocephalae 100mg+ Fructus Mori 50mg+ zinc 0.1mg+ ferrum 0.1mg+ selenium 0.001mg+VB 10.1mg+ VB 20.1mg+ nicotiamide 0.2mg+VB 60.08mg +VB 120.0001mg+ folic acid 0.008mg/ days | 12 | 29.7% |
Annotate: each group was tested by dosage feed in the table respectively in 60 days in subordinate list 1, the subordinate list 2; Consumption converts by per kilogram of body weight in the table.
Select 50 of newly-married healthy womens, 25 years old mean age, take this compositions continuously from beginning in pregnant preceding 3 months, followed up a case by regular visits to none routine birth defect in 6 months to the baby due; With associated materials statistics contrasts, birth defect youngster account for the newborn population sum 4-6% there were significant differences.
Can obviously find out from table 1, table 2, this compositions is by Chinese medicine component in rat/mouse labyrinth test and the compositions and the contrast of vitamin added elements component, the statistical result of mistake percentage rate, the function of this composition for improved memory is better than Chinese medicine component or vitamin added elements component; With the blank group significant difference is arranged relatively.
Claims (6)
1, a kind of pharmaceutical composition that is used to prevent birth defect and improves memory is characterized in that it is made by weight ratio by following raw materials according:
The Rhizoma Atractylodis Macrocephalae 300-15000mg,
Fructus Mori 300-10000mg,
Folic acid 0.1-1mg,
Vitamin B
60.5-10mg,
Vitamin B
120.001-0.025mg,
Vitamin B
10.5-20mg,
Vitamin B
20.5-20mg,
Nicotiamide 5-50mg,
Pantothenic acid 0-20mg,
Biotin 0-0.1mg,
Zinc 5-20mg,
Selenium 0.015-0.1mg,
Ferrum 5-20mg,
Chromium 0-0.15mg,
Copper 0-1.5mg,
Molybdenum 0-0.06mg,
Manganese 0-3mg.
2, the pharmaceutical composition that is used to prevent birth defect and improves memory according to claim 1 is characterized in that it is made by weight ratio by following raw materials according:
The Rhizoma Atractylodis Macrocephalae 300-15000mg,
Fructus Mori 300-10000mg,
Folic acid 0.1-1mg,
Vitamin B
60.5-10mg,
Vitamin B
120.001-0.025mg,
Vitamin B
10.5-20mg,
Vitamin B
20.5-20mg,
Nicotiamide 5-50mg,
Pantothenic acid 0-20mg,
Biotin 0-0.1mg,
Zinc 5-20mg,
Selenium 0.015-0.1mg,
Ferrum 5-20mg,
Chromium 0.015-0.15mg,
Copper 0-1.5mg,
Molybdenum 0-0.06mg,
Manganese 0-3mg.
3, the pharmaceutical composition that is used to prevent birth defect and improves memory according to claim 1 is characterized in that it is made by weight ratio by following raw materials according:
The Rhizoma Atractylodis Macrocephalae 300-15000mg,
Fructus Mori 300-10000mg,
Folic acid 0.1-1mg,
Vitamin B
60.5-10mg,
Vitamin B
120.001-0.025mg,
Vitamin B
10.5-20mg,
Vitamin B
20.5-20mg,
Nicotiamide 5-50mg,
Pantothenic acid 0-20mg,
Biotin 0-0.1mg,
Zinc 5-20mg,
Selenium 0.015-0.1mg,
Ferrum 5-20mg,
Chromium 0.015-0.15mg,
Copper 0-1.5mg,
Molybdenum 0.02-0.06mg,
Manganese 0-3mg.
4, the pharmaceutical composition that is used to prevent birth defect and improves memory according to claim 1 is characterized in that it is made by weight ratio by following raw materials according:
The Rhizoma Atractylodis Macrocephalae 300-15000mg,
Fructus Mori 300-10000mg,
Folic acid 0.1-1mg,
Vitamin B
60.5-10mg,
Vitamin B
120.001-0.025mg,
Vitamin B
10.5-20mg,
Vitamin B
20.5-20mg,
Nicotiamide 5-50mg,
Pantothenic acid 0-20mg,
Biotin 0-0.1mg,
Zinc 5-20mg,
Selenium 0.015-0.1mg,
Ferrum 5-20mg,
Chromium 0.015-0.15mg,
Copper 0.5-1.5mg,
Molybdenum 0.02-0.06mg,
Manganese 0-3mg.
5, the pharmaceutical composition that is used to prevent birth defect and improves memory according to claim 1 is characterized in that it is made by weight ratio by following raw materials according:
The Rhizoma Atractylodis Macrocephalae 300-15000mg,
Fructus Mori 300-10000mg,
Folic acid 0.1-1mg,
Vitamin B
60.5-10mg,
Vitamin B
120.001-0.025mg,
Vitamin B
10.5-20mg,
Vitamin B
20.5-20mg,
Nicotiamide 5-50mg,
Pantothenic acid 0-20mg,
Biotin 0-0.1mg,
Zinc 5-20mg,
Selenium 0.015-0.1mg,
Ferrum 5-20mg,
Chromium 0.015-0.15mg,
Copper 0.5-1.5mg,
Molybdenum 0.02-0.06mg,
Manganese 1-3mg.
6, the pharmaceutical composition that is used to prevent birth defect and improves memory according to claim 1 is characterized in that it is made by weight ratio by following raw materials according:
The Rhizoma Atractylodis Macrocephalae 300-15000mg,
Fructus Mori 300-10000mg,
Folic acid 0.1-1mg,
Vitamin B
60.5-10mg,
Vitamin B
120.001-0.025mg,
Vitamin B
10.5-20mg,
Vitamin B
20.5-20mg,
Nicotiamide 5-50mg,
Pantothenic acid 2-20mg,
Biotin 0.01-0.1mg,
Zinc 5-20mg,
Selenium 0.015-0.1mg,
Ferrum 5-20mg,
Chromium 0.015-0.15mg,
Copper 0.5-1.5mg,
Molybdenum 0.02-0.06mg,
Manganese 1-3mg.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2008102238606A CN101375944A (en) | 2008-10-08 | 2008-10-08 | Pharmaceutical combination for preventing birth-defect and improving memory |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2008102238606A CN101375944A (en) | 2008-10-08 | 2008-10-08 | Pharmaceutical combination for preventing birth-defect and improving memory |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101375944A true CN101375944A (en) | 2009-03-04 |
Family
ID=40419790
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2008102238606A Pending CN101375944A (en) | 2008-10-08 | 2008-10-08 | Pharmaceutical combination for preventing birth-defect and improving memory |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101375944A (en) |
-
2008
- 2008-10-08 CN CNA2008102238606A patent/CN101375944A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101301332A (en) | Pharmaceutical combination for preventing birth-defect and improving memory | |
CN101390903A (en) | Medicine composition for preventing the birth defect and improving the memory | |
CN101366766A (en) | Pharmaceutical combination for preventing birth defect and improving anamnesis | |
CN101375944A (en) | Pharmaceutical combination for preventing birth-defect and improving memory | |
CN101375925A (en) | Pharmaceutical combination for preventing birth-defect and improving memory | |
CN101375943A (en) | Pharmaceutical combination for preventing birth-defect and improving memory | |
CN101306048A (en) | Medicine composition for preventing the birth defect and improving the memory | |
CN101375942A (en) | Pharmaceutical combination for preventing birth-defect and improving memory | |
CN101293006A (en) | Pharmaceutical composition for bearing and rearing better children, preventing birth defect and improving anamnesis | |
CN101301333A (en) | Pharmaceutical combination for preventing birth-defect and improving memory | |
CN101390926A (en) | Medicine composition for preventing the birth defect and improving the memory | |
CN101375921A (en) | Pharmaceutical combination for preventing birth-defect and improving memory | |
CN101406506A (en) | Pharmaceutical combination for preventing birth-defect and improving memory | |
CN101366835A (en) | Medicament composition for preventing birth defection and improving memory | |
CN101390898A (en) | Medicine composition for preventing the birth defect and improving the memory | |
CN101590094A (en) | The pharmaceutical composition that is used to prevent birth defect and improves memory | |
CN101306050A (en) | Medicine composition for preventing the birth defect and improving the memory | |
CN101347485A (en) | Pharmaceutical combination for preventing birth-defect and improving memory | |
CN101390927A (en) | Medicine composition for preventing the birth defect and improving the memory | |
CN101366865A (en) | Medicament composition for preventing birth defect and improving memory | |
CN101385757A (en) | Medicine composition for preventing the birth defect and improving the memory | |
CN101375922A (en) | Pharmaceutical combination for preventing birth-defect and improving memory | |
CN101375897A (en) | Pharmaceutical combination for preventing birth-defect and improving memory | |
CN101371860A (en) | Pharmaceutical combination for preventing birth-defect and improving memory | |
CN101390888A (en) | Medicine composition for preventing the birth defect and improving the memory |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090304 |